Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2021

View Archived Issues

Lysogene initiates phase I/II study of LYS-GM101 gene therapy in infantile GM1 gangliosidosis

FDA approves IND for KRAS G12C inhibitor JAB-21822

SAN-903 reduces lung inflammation and fibrosis in mouse model of IPF

First direct KRAS G12V(ON) inhibitors developed at Revolution Medicines

New model allows exploration of PHF21B gene function

Promising part A data from MOMENTUM study of SRP-5051 in DMD

Promising safety data from first dose cohort of phase I study evaluating DSG3-CAART

Shanghai HaiHe Biopharma patents BRD4 inhibitors

Janssen Biotech presents DHODH inhibitors

New IDH1 inhibitors presented by Shanghai Meton Pharmaceutical

Kallyope discloses GPR119 agonists

Avacta Life Sciences presents new PD-L1 inhibitors

Topline data presented from first cohort of phase Ib trial of RGLS-4326

BRM-421: human study data for dry eye syndrome

Novavax announces pediatric expansion of pivotal PREVENT-19 trial of NVX-CoV-2373

Ongoing TOGETHER platform study will evaluate Lambda in outpatients with COVID-19

HORNBILL phase I data reported for BI-764524

DF-6002 shows robust antitumor activity in preclinical models

Discovery and optimization of novel N-pyrimidines as IDO1 inhibitors

Administration of 5,6-DiHETE, an endogenous TRPV4 antagonist, contributes to colitis healing in mice

Mitochondrial peptide causes septic shock nosocomials, mortality

LRRK2 inhibitor DNL-151 well tolerated in healthy volunteers and patients with PD

XBiotech and INSERM collaborate on phase II/III trial of XB-2001

Vaxart reports phase I findings on oral COVID-19 vaccine VXA-CoV2-1

FDA clears IND for phase II trial of CT-868 in overweight and obese patients with type 2 diabetes

FDA approves Kloxxado for opioid overdose

Merus begins phase I/II study of MCLA-129 in NSCLC and solid tumors

PXS-5505 to enter preclinical evaluation for glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...